Goldstein Advisors LLC Sells 651 Shares of Natera, Inc. (NASDAQ:NTRA)

Goldstein Advisors LLC lowered its stake in Natera, Inc. (NASDAQ:NTRA) by 22.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,187 shares of the medical research company’s stock after selling 651 shares during the quarter. Goldstein Advisors LLC’s holdings in Natera were worth $278,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Itau Unibanco Holding S.A. acquired a new stake in shares of Natera in the second quarter valued at about $28,000. Quarry LP increased its position in shares of Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 108 shares during the last quarter. Tobam acquired a new stake in shares of Natera in the second quarter valued at about $74,000. Finally, DekaBank Deutsche Girozentrale acquired a new stake in shares of Natera in the first quarter valued at about $83,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Trading Down 1.3 %

Shares of NTRA stock opened at $117.67 on Friday. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The stock has a market cap of $14.55 billion, a P/E ratio of -48.03 and a beta of 1.53. The stock has a 50 day simple moving average of $123.24 and a 200 day simple moving average of $111.34. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $133.54.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.39. The business had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The firm’s revenue for the quarter was up 58.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.97) earnings per share. On average, research analysts predict that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Insider Activity at Natera

In related news, insider Daniel Rabinowitz sold 1,057 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $102.77, for a total value of $108,627.89. Following the completion of the sale, the insider now directly owns 206,400 shares in the company, valued at approximately $21,211,728. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Natera news, insider Daniel Rabinowitz sold 1,057 shares of the company’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $102.77, for a total transaction of $108,627.89. Following the completion of the sale, the insider now directly owns 206,400 shares in the company, valued at $21,211,728. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jonathan Sheena sold 2,700 shares of the company’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $113.82, for a total value of $307,314.00. Following the sale, the insider now owns 299,441 shares of the company’s stock, valued at $34,082,374.62. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,149 shares of company stock worth $6,007,018. Company insiders own 7.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. TD Cowen lifted their target price on Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Leerink Partners boosted their price target on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research report on Friday. Stephens reissued an “overweight” rating and set a $125.00 price target on shares of Natera in a research report on Friday, August 9th. Finally, Morgan Stanley boosted their price target on Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $124.44.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.